VIDA Diagnostics has announced a new strategic partnership with Riverain Technologies at the Radiologic Society of North America (RSNA) meeting, bringing Riverain’s ClearRead CT cardiothoracic AI imaging suite into the VIDA Intelligence Platform. This platform is used globally to support clinical trials by ensuring high-quality imaging biomarkers and streamlined operational workflows. Riverain joins existing VIDA partners such as Thirona, National Jewish Health, and Polarean, expanding a unified ecosystem of advanced imaging technologies accessible through a single, secure platform.
By integrating these tools, VIDA offers pharmaceutical science teams a centralized solution for precision imaging biomarkers, reducing the complexity of managing multiple AI vendors while standardizing biomarker outputs across trial sites. VIDA CEO Susan Wood, PhD, said the partnership delivers the clinically rich imaging needed to better understand how therapies interact with major chest diseases such as COPD, cardiovascular disease, and lung cancer. Riverain CEO Steve Worrell added that ClearRead’s expansion into VIDA’s platform strengthens the data available to life sciences teams and helps accelerate therapeutic innovation.
The partnership supports VIDA’s broader effort to address the “Big Three” chest diseases—cardiovascular disease, COPD, and lung cancer—which account for roughly 40% of global deaths. Because these conditions often overlap—COPD doubles heart attack risk, and up to 80% of lung cancer cases are preceded by COPD—the ability to analyze comorbidities is critical. ClearRead CT’s AI algorithms provide detailed insights and quantifiable biomarkers for pulmonary nodules, coronary artery calcification, and hypodense lung tissue, helping researchers detect and track these interconnected diseases more effectively.
Click here to read the original news story.